clinical trial · NCT06313593
A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms
Myeloproliferative NeoplasmsINCB160058Standard disease-directed therapy
brief summary
This study is being conducted to assess the Safety, Tolerability, and Pharmacokinetics of INCB160058 in Participants With Myeloproliferative Neoplasms.
started
Aug 8, 2024
primary completion
Oct 9, 2028
completion
Oct 9, 2028
last updated
Apr 6, 2026
official title
A Phase 1, Open-Label, Multicenter Study of INCB160058 in Participants With Myeloproliferative Neoplasms
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol